Advertisement

Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients

  • Claudia Fabiani
  • Antonio Vitale
  • Donato Rigante
  • Giacomo Emmi
  • Alice Bitossi
  • Giuseppe Lopalco
  • Jurgen Sota
  • Silvana Guerriero
  • Ida Orlando
  • Stefano Gentileschi
  • Florenzo Iannone
  • Bruno Frediani
  • Mauro Galeazzi
  • Lorenzo Vannozzi
  • Gian Marco Tosi
  • Luca Cantarini
Original Article
  • 51 Downloads

Abstract

To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical, instrumental, and therapeutic data from patients enrolled were collected at the start of treatment, at 12-month follow-up, and at the last follow-up assessment. One hundred seven patients (46 females, 187 eyes) were enrolled, 66 (61.7%) treated with ADA and 41 (38.3%) with IFX. Bilateral involvement was observed in 80 cases. The mean follow-up was 26.45 ± 21.71 months for ADA patients and 56.60 ± 56.04 months for IFX patients. The overall decrease of uveitis frequency during the first 12 months of treatment was 66.7% in the IFX group and 84.2% in the ADA group, compared to the previous 12 months (p = 0.09). A significantly higher corticosteroid dosage was found among patients treated with ADA at the last follow-up visit (p = 0.008). The percentage of patients co-administered with corticosteroids was significantly higher among ADA patients both at the 12-month visit (p = 0.03) and at the last visit (p = 0.0004). The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.

Keywords

Behçet’s disease Macular edema Retinal vasculitis TNF-blocking antibodies Uveitis 

Notes

Compliance with ethical standards

The study has been approved by the Ethics Committee of Azienda Ospedaliera Universitaria Senese, Siena, Italy. The study protocol was conformed to the tenets of the Declaration of Helsinki and informed consent was obtained from all patients enrolled.

Disclosures

None.

References

  1. 1.
    Rathinam SR, Namperumalsamy P (2007) Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol 55:173–183CrossRefPubMedGoogle Scholar
  2. 2.
    Lopalco G, Venerito V, Sota J, Rigante D, Guerriero S, Orlando I, Franceschini R, Favale R, Lapadula G, Castelli B, Frediani B, Galeazzi M, La Torre F, Iannone F, Tosi GM, Fabiani C, Cantarini L (2018) Epidemiological profile of non-infectious uveitis from the rheumatologist’s perspective: a survey from two tertiary referral centres in Italy. Clin Exp Rheumatol (in press)Google Scholar
  3. 3.
    Fabiani C, Vitale A, Orlando I, Capozzoli M, Fusco F, Rana F, Franceschini R, Sota J, Frediani B, Galeazzi M, Marco Tosi G, Cantarini L (2017) Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy. Isr Med Assoc J 19:478–483PubMedGoogle Scholar
  4. 4.
    Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, Davis JL, Ramanan AV, Sonoda KH, Carreño E, Nascimento H, Salah S, Salek S, Siak J, Steeples L, Fundamentals of Care for Uveitis International Consensus Group (2018) Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitiS (FOCUS) initiative. Ophthalmology 125:757–773.  https://doi.org/10.1016/j.ophtha.2017.11.017 CrossRefPubMedGoogle Scholar
  5. 5.
    Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders Ophthalmology 121:785-96.e3Google Scholar
  6. 6.
    Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375:932–943.  https://doi.org/10.1056/NEJMoa1509852 CrossRefPubMedGoogle Scholar
  7. 7.
    Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183–1192.  https://doi.org/10.1016/S0140-6736(16)31339-3 CrossRefPubMedGoogle Scholar
  8. 8.
    AbbVie International. Prescribing information Humira. http://www.rxabbvie.com/pdf/humira.pdf; 2017
  9. 9.
    AbbVie Limited. Humira 40 mg/0.4 ml pre-filled syringe and pre-filled pen. https://www.medicines.org.uk/emc/medicine/31860; 2017
  10. 10.
    Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M (2008) Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial. Rheumatol Int 29:53–57.  https://doi.org/10.1007/s00296-008-0606-8 CrossRefPubMedGoogle Scholar
  11. 11.
    Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G (2011) One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs. Rheumatol Int 31:33–37.  https://doi.org/10.1007/s00296-009-1213-z CrossRefPubMedGoogle Scholar
  12. 12.
    Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Sota J, Vannozzi L, di Scala G, Guerriero S, Orlando I, Franceschini R, Capozzoli M, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2018) Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol 37:1715–1720.  https://doi.org/10.1007/s10067-018-4092-4 CrossRefPubMedGoogle Scholar
  13. 13.
    Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm 3:1–6.  https://doi.org/10.1080/09273948.2017.1391297 Google Scholar
  14. 14.
    Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Capozzoli M, Fusco F, Rana F, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L (2018) Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol.  https://doi.org/10.1007/s10067-018-4069-3
  15. 15.
    Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, Bienvenu B, Abad S, Rigolet A, Deroux A, Sene D, Perlat A, Marie I, Feurer E, Hachulla E, Fain O, Clavel G, Riviere S, Bouche PA, Gueudry J, Pugnet G, Le Hoang P, Resche Rigon M, Cacoub P, Bodaghi B, Saadoun D, Network FU (2016) Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 68:1522–1530.  https://doi.org/10.1002/art.39667 CrossRefPubMedGoogle Scholar
  16. 16.
    Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Behçet Network (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74.  https://doi.org/10.1016/j.jaut.2015.06.005 CrossRefPubMedGoogle Scholar
  17. 17.
    Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, Rigante D, Cantarini L (2017) Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451–455.  https://doi.org/10.1007/s10067-016-3417-4 CrossRefPubMedGoogle Scholar
  18. 18.
    Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516CrossRefPubMedGoogle Scholar
  19. 19.
    Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR (2007) Cross-cultural adaptation of the Behçet’s disease current activity form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263–1267.  https://doi.org/10.1007/s10067-006-0484-y CrossRefPubMedGoogle Scholar
  20. 20.
    Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, Dijkmans B, Dougados M, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Rudwaleit M (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68:784–788.  https://doi.org/10.1136/ard.2008.101501 CrossRefPubMedGoogle Scholar
  21. 21.
    Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Bitossi A, Orlando I, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2018) Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol.  https://doi.org/10.1007/s10067-018-4133-z
  22. 22.
    Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575–1581.  https://doi.org/10.1016/j.ophtha.2012.02.018 CrossRefPubMedGoogle Scholar
  23. 23.
    Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L (2017) Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183–189.  https://doi.org/10.1007/s10067-016-3480-x CrossRefPubMedGoogle Scholar
  24. 24.
    Mackensen F, Heinz C, Jakob E, Grewing V, Lorenz HM, Heiligenhaus A, Max R, Becker MD (2017) Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul Immunol Inflamm 1-8.  https://doi.org/10.1080/09273948.2017.1411518
  25. 25.
    Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Kempen JH, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (2014) Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121:588–95.e1.  https://doi.org/10.1016/j.ophtha.2013.09.023 CrossRefPubMedGoogle Scholar
  26. 26.
    Ossewaarde-van Norel A, Rothova A (2011) Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm 19:75–83.  https://doi.org/10.3109/09273948.2010.509530 CrossRefPubMedGoogle Scholar
  27. 27.
    Rothova A (2002) Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10:239–246CrossRefPubMedGoogle Scholar
  28. 28.
    Basu S, Monira S, Modi RR, Choudhury N, Mohan N, Padhi TR, Balne PK, Sharma S, Panigrahi SR (2014) Degree, duration, and causes of visual impairment in eyes affected with ocular tuberculosis. J Ophthalmic Inflamm Infect 4:3.  https://doi.org/10.1186/1869-5760-4-3 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332–336CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Claudia Fabiani
    • 1
  • Antonio Vitale
    • 2
  • Donato Rigante
    • 3
  • Giacomo Emmi
    • 4
  • Alice Bitossi
    • 5
  • Giuseppe Lopalco
    • 6
  • Jurgen Sota
    • 2
  • Silvana Guerriero
    • 7
  • Ida Orlando
    • 2
  • Stefano Gentileschi
    • 2
  • Florenzo Iannone
    • 6
  • Bruno Frediani
    • 2
  • Mauro Galeazzi
    • 2
  • Lorenzo Vannozzi
    • 5
  • Gian Marco Tosi
    • 1
  • Luca Cantarini
    • 2
  1. 1.Ophthalmology Unit, Department of Medicine, Surgery and NeuroscienceUniversity of SienaSienaItaly
  2. 2.Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and NeurosciencesUniversity of SienaSienaItaly
  3. 3.Institute of PediatricsUniversità Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli I.R.C.C.SRomeItaly
  4. 4.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  5. 5.Department of Surgery and Translational Medicine, Eye ClinicUniversity of FlorenceFlorenceItaly
  6. 6.Interdisciplinary Department of Medicine, Rheumatology UnitUniversity of BariBariItaly
  7. 7.Department of Ophthalmology and OtolaryngologyUniversity of BariBariItaly

Personalised recommendations